ZEO ScientifiX Partners With Pluri to Expand US Regenerative Medicine Business

Bitget2026/10/26 11:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ZEO ScientifiX entered a definitive partnership with Pluri to expand U.S. regenerative medicine manufacturing and commercialization.
Pluri will receive common stock representing 50% ownership at closing in exchange for defined manufacturing technology and know-how rights.
The agreement provides exclusive U.S. rights to Pluri's Cellav aesthetic product line, including future offerings.
Pluri will retain ownership of its underlying technology and intellectual property.
Closing is expected in the fourth quarter of 2026, subject to approvals and other conditions; neither company's stockholders need to approve.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260700PRIMZONEFULLFEED9852874) on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03